Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs MOR 107 (Primary)
- Indications Diabetic nephropathies; Fibrosis
- Focus Adverse reactions; First in man
- Sponsors Lanthio Pharma
- 09 Feb 2018 Last checked against ClinicalTrials.gov record.
- 06 Feb 2018 Status changed from recruiting to discontinued as part 1 was completed successfully and part 2 was not conducted.
- 03 Mar 2017 New trial record